КАРДИОВАСКУЛЯРНЫЕ И МЕТАБОЛИЧЕСКИЕ ВЗАИМОСВЯЗИ ХРОНИЧЕСКОЙБОЛЕЗНИПОЧЕК

doi: 10.25005/3078-5022-2025-2-2-235-243
Авторы:
РАШИДОВ И. М., ОЛИМОВ О. З
ГОУ «Таджикский институт профилактической медицины», ГУ НМЦ РТ «Шифобахш», Кафедраурологии ГОУ «ТГМУ им. Абуали ибни Сино», Республика Таджикистан

В данной статье представлены современные взгляды на эпидемиологическуюзначимость, кардиоренальные механизмы, традиционные и нетрадиционные факторыриска,метаболические аспекты, молекулярные и сосудистые механизмы и клиническиестратегиихронической болезни почек (ХБП).

Заключение. ХБП является не только нефрологической, но и системнойпроблемой, гдекардиоваскулярные и метаболические осложнения выходят на первый план. Пониманиепатогенеза и внедрение новых терапевтических стратегий позволяютсущественноулучшитьпрогноз пациентов.

Ключевые слова

Хроническая болезнь почек, сердечно-сосудистые заболевания,кардиоренальный синдром, факторы риска, скорость клубочковой фильтрации

Литература

  1. Khronicheskaya bolezn' pochek: uchebnoye posobiye [Chronic kidney disease: a textbook] / sost. IG. Nikitin [i dr.]. M.: RNIMU im. N.I. Pirogova Minzdrava Rossii. 2019:136.
  2. Vikulova OK. i dr. Epidemiologiya khronicheskoy bolezni pochek u patsiyentov s sakharnym diabetom v Rossiyskoy Federatsii: dannyye federal'nogo registra sakharnogo diabeta, dinamika 2010–2022 gg. [Epide-miology of chronic kidney disease in patients with diabetes mellitus in the Russian Federation: data from the federal diabetes registry, dynamics 2010–2022] Sakharnyy diabet. 2023:5. URL: https://cyberleninka.ru/article/n/epidemiologiya-hronicheskoy-bolezni-pochek-u-patsientov-s-saharnym-diabetom-v-rossiyskoy-federatsii-dannye-federalnogo-registra
  3. Aringazina AM, i dr. Khronicheskaya bolezn' pochek: rasprostranennost' i faktory riska (obzor litera-tury) [Chronic kidney disease: prevalence and risk factors (literature review)]. Analiz riska zdorov'yu.2020;2. URL: https://cyberleninka.ru/article/n/hronicheskaya-bolezn-pochek-rasprostranennost-i-faktory-riska-obzor-literatury
  4. Khadzegova A.B. Funktsiya pochek pri serdechnoy nedostatochnosti — prediktor vybora blokatorov RAAS [Kidney function in heart failure — a predictor of the choice of RAAS blockers]. RMZH. Meditsinskoye obozreniye. 2023;7,1:30-35.
  5. Shukurova SM, Rashidov IM. Khronicheskaya bolezn' pochek i serdechno-sosudistyye zabolevaniya: yest' li svyaz'? [Chronic kidney disease and cardiovascular diseases: is there a connection?] Zdravookhraneniye Tadzhikistana. 2024;3:111-118. https://doi.org/10.52888/0514-2515-2024-362-3-111-118
  6. Shukurova SM, Rashidov IM, Kosimova SD. Kliniko-laboratornyye prediktory progressirovaniya khronicheskoy bolezni pochek [Clinical and laboratory predictors of chronic kidney disease progression]. Zdravookhraneniye Tadzhikistana.2021;2:98-104.
  7. Mullabayeva G, Mukhamedova SH. Nekotoryye aspekty kardiorenal'nogo sindroma [Some aspects of cardiorenal syndrome]. Meditsina i innovatsii. 2022;2:122-127.
  8. Zoccali C, et al. Working Group of the European Renal Association. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine. Cardiovasc Res. 2023,Sep 5;119(11):2017-2032. doi: 10.1093/cvr/cvad083.
  9. Rangaswami J, et al. Cardiorenal syndrome: classification, pathophysiology and treatment strategies : A Scientific Statement From the American Heart Association. Circulation. 2019,Apr 16;139(16):e840-e878. doi: 10.1161/CIR.0000000000000664.
  10. Matsushita K, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes : a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015,Jul;3(7):514-25. doi: 10.1016/S2213-8587(15)00040-6.
  11. Koppe L, Fouque D, Soulage C. Metabolic abnormalities in diabetes and kidney disease: role of uremic toxins. Curr. Diab. Rep.2018;18(10):97. doi: 10.1007/s11892-018-1064-7.
  12. Zhu T, et al. The role of microbial metabolites in diabetic kidney disease.Heliyon.2023,Jul 4;9(7):e17844. doi: 10.1016/j.heliyon.2023.e17844.
  13. London GM. Arterial stiffness in chronic kidney disease and end-stage renal disease. Blood Purif. 2018;45(1-3):154–158. doi: 10.1159/000485146.
  14. Cicero LL, et al. Inflammation and arterial stiffness as Drivers of Cardiovascular Risk in Kidney Disease. Cardiorenal Med. 2025;15(1):29-40. doi: 10.1159/000542965.
  15. Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816.
  16. Perkovic V, et al. Semaglutide in patients with type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 2024;391:109–121. DOI: 10.1056/NEJMoa2403347.
  17. Rastogi А, et al. Management of Hyperphosphatemia in End-Stage Renal Disease: A New Para-digm.Journal of Renal Nutrition.2021;31(1):21-34. doi.org/10.1053/j.jrn.2020.02.003.
  18. Zhao SJ, et al. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Ann Palliat Med.2022;11(4):1264-1277. doi: 10.21037/apm21-1943.
  19. El Chamieh C, Liabeuf S, Massy Z. Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings? Toxins. 2022; 14(4):280. https://doi.org/10.3390/toxins14040280
  20. Onal EM, et al. Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension. Clin Exp Hypertens. 2017;39:197–209. doi: 10.1080/10641963.2016.1246565
  21. Matsushita K, et al. Chronic kidney disease measures and the risk of abdominal aortic aneurysm. Athero-sclerosis. 2018;279:107–113. doi: 10.1016/j.atherosclerosis.2018.08.043
  22. Maini R, et al. Persistent underrepresentation of kidney disease in randomized, controlled trials of cardio-vascular disease in the contemporary era. J Am Soc Nephrol. 2018;29:2782–2786. doi: 10.1681/ASN.2018070674.
  23. De Vriese AS, et al. Multicenter randomized controlled trial of vitamin K antagonist replacement by riva-roxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie Study. J Am Soc Nephrol.2020;31:186–196. doi: 10.1681/ASN.2019060579.
  24. Sakaguchi Y, et al. A randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD. J Am Soc Nephrol. 2019;30:1073–1085. doi: 10.1681/ASN.2018111150
  25. Amdur RL, Feldman HI, Dominic EA; CRIC Study Investigators. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC Study. Am J Kidney Dis. 2019;73:344–353. doi: 10.1053/j.ajkd.2018.09.012
  26. Urena-Torres P, et al. Valvular heart disease and calcification in CKD: more common than appreciat-ed. Nephrol Dial Transplant. 2019;1:1–8.
  27. Bangalore S, et al.; ISCHEMIA-CKD Research Group. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. 2020;382:1608–1618. doi: 10.1056/NEJMoa1915925.
  28. Charytan DM, et al. Hemodialysis Novel Therapies Consortium. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int. 2019;95:973–982. doi: 10.1016/j.kint.2018.08.034.
  29. Hammer F, Malzahn U, Donhauser J; MiREnDa Study Group. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.Kidney Int. 2019;95:983–991. doi: 10.1016/j.kint.2018.11.025.
  30. Siontis GCM, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treat-ment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 2019;40:3143–3153. doi: 10.1093/eurheartj/ehz275.
  31. Mack MJ, Leon MB, Thourani VH; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–1705. doi: 10.1056/NEJMoa1814052.
  32. Popma JJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N.Engl.J.Med.2019;380:1706–1715. doi: 10.1056/NEJMoa1816885.
  33. Patel KK, et al. // Characteristics and outcomes of patients with aortic stenosis and chronic kidney dis-ease. J Am Heart Assoc. 2019;8:e009980. doi: 10.1161/JAHA.118.009980.

Сведения об авторах

Рашидов Исмоил Махмадалиевич
к.м.н., заведующий отделения нефрологии и гемодиализа ГУ НМЦ РТ «Шифобахш», докторант ГУ «Таджикский научно-исследовательский институт профилакти-ческой медицины»;
Тел.: +992903508008;
E-mail: nefrontj@gmail.com

Информация об источнике поддержки в виде грантов, оборудования, лекарственных препаратов
Финансовой поддержки со стороны компаний–производителей лекарственных препаратов и меди-цинского оборудования авторы не получали.

Конфликт интересов: отсутствует

Адрес для корреспонденции

Рашидов Исмоил Махмадалиевич
к.м.н., заведующий отделения нефрологии и гемодиализа ГУ НМЦ РТ «Шифобахш», докторант ГУ «Таджикский научно-исследовательский институт профилакти-ческой медицины»;

Тел.: +992903508008

E-mail: nefrontj@gmail.com

◄ Возврат к списку